Head-to-head · WeighScore
MyStart Health vs Willow
By GLP-1 ScorecardUpdated
Score comparison
MyStart Health has the higher recorded score — 61.3/100 to 58.2/100.
MyStart Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MyStart Health offers all-inclusive compounded semaglutide and tirzepatide at $299/month with a price-lock guarantee, same-day physician consultations, and 24/7 care team access.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | MyStart Health | Willow |
|---|---|---|
| WeighScore | 61.3/100 | 58.2/100 |
| Grade | C | C |
| Site position | #337 | #342 |
| Semaglutide | $299/mo (all doses, compounded) | $299/mo (starting dose, compounded) |
| Tirzepatide | $299/mo (all doses, compounded) | $399/mo (starting dose, compounded) |
| Coverage | Coverage not published | Multi-state; confirm location and preparation |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #337 · C
FDAWarning letter issued to Matthew Stern, CEO MyStart Health LLC. in September 2025. See the FDA warning-letter database.
Strengths
- Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
- Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- 24/7 care team access with unlimited clinician messaging included
- LegitScript certified
- Clear Section 503A compounding disclosure on every landing page
What to consider
- Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
- Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
- Very new company (incorporated May 2024) with a limited track record
- FDA issued Matthew Stern, CEO MyStart Health LLC. a warning letter in September 2025; the letter is public in FDA's warning-letter database
Site position #342 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
What to consider
- Dose and refill changes may change the bill
- Confirm the assigned pharmacy and cancellation before processing
Featured provider
Willow
Willow scores 58.2/100 (C). Telehealth provider offering compounded GLP-1 medications in both tablet and injectable formats.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.